Recent Quotes (30 days)

You have no recent quotes
chg | %

Great Basin Scientific Inc  

(Public, NASDAQ:GBSN)   Watch this stock  
Find more results for GBSN
0.0000 (0.00%)
Oct. 10 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 1.60M
P/E     -
Div/yield     -
EPS -227.21M
Shares 5.34M
Beta     -
Inst. own 0%

Key stats and ratios

Q1 (Mar. '17) 2016
Net profit margin 2588.36% -2924.69%
Operating margin -703.50% -1911.13%
EBITD margin - -1031.67%
Return on average assets 168.06% -174.88%
Return on average equity - -
Employees 70 -
CDP Score - -


420 E South Temple Ste 520
SALT LAKE CITY, UT 84111-1362
United States - Map
+1-801-9901055 (Phone)
+1-801-9901051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C. diff) and Group B Strep. Its system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. Its other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). The Company also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. It markets a platform of molecular testing in small to medium sized hospitals.

Officers and directors

David Spafford Executive Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Robert Jenison Senior Vice President - Research, Chief Technology Officer
Age: 50
Bio & Compensation  - Reuters
Ryan Ashton President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Kirk K. Calhoun Independent Director
Age: 73
Bio & Compensation  - Reuters
Sam Chawla Independent Director
Age: 41
Bio & Compensation  - Reuters
Ronald K. Labrum Independent Director
Age: 60
Bio & Compensation  - Reuters